Experimental combo for tough-to-treat colon cancer trial pulled before start
NCT ID NCT06557278
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 21 times
Summary
This study was designed for people with advanced colorectal cancer that had stopped responding to standard treatments. It aimed to test a combination of two experimental immunotherapies (AlloStim and an anti-PDL1 drug) to see if they could shrink tumors or help people live longer. However, the trial was withdrawn before enrolling any participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hirschfield Oncology Center
Brooklyn, New York, 11206, United States
-
Mt. Sinai Comprehensive Cancer Center
Miami Beach, Florida, 33140, United States
-
New York Cancer and Blood Specialists
Shirley, New York, 11967, United States
Conditions
Explore the condition pages connected to this study.